Taking a patient-first, precision medicine approach to orphan drug development

Epygenix Therapeutics is a precision medicine biotech company developing drugs to treat Dravet syndrome and other rare forms of genetic epilepsy. Recognizing the unmet needs of patients with these diseases, Epygenix has adopted a drug-repurposing strategy intended to accelerate research and development, and is approaching the start of a phase 1/2 trial of its lead candidate.

Page of

Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.

No comments yet.